Systematic Review and Meta-analysis of Executive Functions in Preschool and School-Age Children With Neurofibromatosis Type 1.

Objectives: Neurofibromatosis type 1 (NF1) is a genetic disorder in which the most frequent complication in children is learning disabilities. Over the past decade, growing arguments support the idea that executive dysfunction is a core deficit in children with NF1. However, some data remain inconsistent.

[Epilepsy and road legislation].

As regards road safety, the doctors have the duty to inform their patients on the affections incompatible, transitorily or in a final way, with control of a vehicle. In the majority of the countries, the very large majority of the epileptics is not in rule with respect to this legislation with regard to the private cars. Moreover, the legislation is too restrictive for the drivers of group 2.

Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study.

Unlabelled: A multicentre, open label, randomised, parallel group study compared the efficacy, tolerability and safety of two dosing regimens, t.i.d.

Epileptic drivers--a study of 1,089 patients.

A longitudinal study of 1,089 epileptic patients followed up by the same specialist between 1965-1991, allowed close observation of the seizures occurring to the patient at the wheel and their consequences and to relate them to detailed epileptological criteria. The results show road accidents caused by epileptic seizures are few and most of them are minor. The repatriation of risks between patients is very uneven.

Epilepsy and driving: an international perspective. Joint Commission on Drivers' Licensing of the International Bureau for Epilepsy and the International League Against Epilepsy.

Individuals with a history of seizures may be granted driving privileges if the risks of future seizure while driving are relatively low. Different nations have defined these risks in a wide variety of ways. Some countries, e.

Long-term treatment of epilepsy: open multicenter trial with progabide in epileptic patients.

A long-term open multicenter trial was carried out in 15 European centers with therapy-resistant epileptics to evaluate the efficacy and safety of progabide, a new antiepileptic GABA receptor agonist; 187 patients, suffering from partial epilepsy (57%), primary generalized epilepsy (20%), secondary generalized epilepsy (21%), and unclassified generalized epilepsy (2%), participated in the study. All patients had a total seizure frequency higher than one per month in spite of standard antiepileptic medication; 46% had a mean partial seizure frequency from daily to weekly. Progabide was administered at a mean daily dose of 30.

[Epileptic seizures after recovery from an epilepsy with rolandic paroxysms (author's transl)].

154 subjects over 13 years of age were examined who had suffered from RPE (epilepsy with rolandic paroxysmal foci) in infancy (87 subjects were 20 years old). Seizures had reappeared 5 times, four of them being apparently, primary generalized motor seizures. Treatment was not resumed in 3 cases which had not had another seizure for 11, 13 and 2 years, respectively.